Molecular Biology and Prevention of Endometrial Cancer
Abstract
To increase our understanding of the molecular aberrations associated with endometrial carcinogenesis and the biologic mechanisms underlying the protective effect of oral contraceptive (OC) therapy. 1) Oligonucleotide microarray analysis was performed on a panel of endometrial cancers. 2) A subset of adenocarcinoma cases from the International DES Registry (IDESR) was analyzed for MSI 3) A case-control study of the CASH database was performed to evaluate the relationship between progestin potency and endometrial cancer risk. 4) An analysis of endometrium samples from cymologous macaques that were exposed to long term progestins was performed. 5) A clinical trial comparing progestin versus placebo is underway that will facilitate investigation of the effects of progestin exposure on the endometrial lining. 1) Different histological types of endometrial cancer have unique genomic expression patterns. 2) The poor quality DNA from the majority of IDESR samples prohibited an adequate analysis of the case set. 3) A case-control study has suggested higher progestin- potency OCs may be more protective than lower progestin potency OCs among women with a larger body habitus. 4) Macaque studies have suggested that induction of apoptosis may be a mechanism underlying the chemoprotective effects of progestin on the endometrium. 5) Regulatory hurdles have resulted in delays in initiation of the clinical trial. Final FDA approval is expected within the next 3-4 months and the original objectives in the statement of work will be addressed.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2006
- Accession Number
- ADA460283
Entities
People
- George L. Maxwell
Organizations
- Henry M. Jackson Foundation for the Advancement of Military Medicine